Prilenia Therapeutics is a clinical stage biotech company developing its lead drug candidate, pridopidine, for Huntington’s Disease and ALS. It was founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders.
Location: Israel, Tel Aviv District, Herzliya
Total raised: $105.5M
Investors 2
| Date | Name | Website |
| 12.01.2023 | Forbion | forbion.co... |
| 23.02.2021 | ALS Invest... | alsinvestm... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.12.2021 | Series B | $43M | - |
| 03.06.2020 | Series A | $62.5M | ALS Invest... |
Mentions in press and media 24
| Date | Title | Description |
| 08.09.2026 | Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s d... |
| 07.07.2026 | Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease | PRECISE-HD (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in Huntington’s Disease (HD)) is designed to further evaluate the efficacy and safety of pridopidine, an oral investigational drug, on disease progression, functi... |
| 26.05.2026 | Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V. today announced a Data Use Agreement (DUA) under which Prilenia will provide CHDI with clinical data from the placebo arms of its PRIDE and PROOF st... |
| 28.04.2026 | Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington... |
| 30.03.2026 | Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS | REVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly progressive participants The design of the potentia... |
| 11.12.2025 | Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS | FDA clearance received to start the pivotal, 500-patient, placebo-controlled Phase 3 “PREVAiLS” study of pridopidine in participants with early, rapidly progressive ALS; US recruitment set to begin early 2026 PREVAiLS (Pridopidine Phase 3 S... |
| 10.10.2025 | Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress | Prilenia and Ferrer will present five posters at the 2025 HSG Huntington’s Disease (HD) Clinical Research Congress, including new analyses of 2-year data following patients not taking antidopaminergic medicines (ADMs) through both double-bl... |
| 06.10.2025 | Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting | Prilenia and Ferrer will unveil their planned pivotal Phase 3 study of pridopidine in ALS at the upcoming Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2025 Annual Meeting, Florida, October 7-10, 2025 Aimed at confirming the en... |
| 25.07.2025 | Prilenia and Ferrer Provide Update on European Regulatory Process for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)-- Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has r... |
| 28.04.2025 | Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets | NAARDEN, The Netherlands and WALTHAM, Mass., 28 April 2025 --- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s... |
Show more